Linearis with its tandem Ventures Fund and Laboratory, is pioneering and supporting discoveries to prevent, detect, and cure diseases through direct investments in innovative AI-powered life sciences companies.

Provides the most comprehensive AI-driven metabolomics diseases signatures

Non-Invasive Assessment of Biomarkers in the Eye. 510(k) & Health Canada approval

Initiation Ph1/2b in basal cell carcinoma

$50M USD AI-drug discovery licensing with GSK